Category: Peptide Q&A
-
Is there evidence that tesamorelin crosses the blood-brain barrier, and what are the implications for central nervous system effects?
Is there evidence that tesamorelin crosses the blood-brain barrier, and what are the implications for central nervous system effects?
-
What are the recommended monitoring parameters for IGF-1, glucose, and lipid levels during tesamorelin therapy?
What are the recommended monitoring parameters for IGF-1, glucose, and lipid levels during tesamorelin therapy?
-
How does tesamorelin affect adipokine profiles such as leptin and adiponectin in patients with visceral fat accumulation?
How does tesamorelin affect adipokine profiles such as leptin and adiponectin in patients with visceral fat accumulation?
-
Tesamorelin: Mechanisms & How It Works
Tesamorelin — Mechanisms & How It Works: evidence-based guide.
-
What is the effect of dose escalation or tapering on GH and IGF-1 levels, and how should dosing be adjusted in elderly or renal-impaired patients?
What is the effect of dose escalation or tapering on GH and IGF-1 levels, and how should dosing be adjusted in elderly or renal-impaired patients?
-
Are there any documented cases of tesamorelin-induced joint pain, carpal tunnel syndrome, or other musculoskeletal side effects?
Are there any documented cases of tesamorelin-induced joint pain, carpal tunnel syndrome, or other musculoskeletal side effects?
-
How do the results of Phase 3 trials like the one published in the Journal of Acquired Immune Deficiency Syndromes compare to real-world observational studies?
How do the results of Phase 3 trials like the one published in the Journal of Acquired Immune Deficiency Syndromes compare to real-world observational s